Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.77 |
| ▸ | ERBB2 | P04626 | 20/20 | 0.77 |
| ▸ | MET | P08581 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2447421 | 0.90 | EGFR (0.86) | EGFRERBB2 | |
| SCHEMBL2445467 | 0.89 | EGFR (0.80) | EGFRERBB2 | |
| SCHEMBL2450475 | 0.89 | EGFR (0.80) | EGFRERBB2 | |
| SCHEMBL2446292 | 0.89 | EGFR (0.80) | EGFRERBB2MET | |
| SCHEMBL2447425 | 0.88 | EGFR (0.86) | EGFRERBB2MET | |
| SCHEMBL2444943 | 0.88 | EGFR (0.81) | EGFRERBB2MET | |
| SCHEMBL2444028 | 0.87 | EGFR (1.00) | EGFRERBB2MET | |
| SCHEMBL2443472 | 0.87 | EGFR (1.00) | EGFRERBB2MET | |
| SCHEMBL2445307 | 0.86 | EGFR (0.81) | EGFRERBB2 | |
| SCHEMBL2446787 | 0.86 | EGFR (1.00) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1446401-B1 | C5-modified indazolylpyrrolotriazines | BRISTOL MYERS SQUIBB CO (US) | 2011-09-14 | — | — | EP | claimed |
| JP-4301440-B2 | — | — | 2009-07-22 | — | — | JP | claimed |
| EP-1446401-A4 | C-5 MODIFIED INDAZOLYLPYRROLOTRIAZINES | BRISTOL MYERS SQUIBB CO (US) | 2006-04-12 | — | — | EP | claimed |
| US-6908916-B2 | C-5 modified indazolylpyrrolotriazines | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-06-21 | — | — | US | claimed |
| JP-2005509030-A | — | — | 2005-04-07 | — | — | JP | claimed |
| EP-1446401-A2 | C-5 MODIFIED INDAZOLYLPYRROLOTRIAZINES | Bristol-Myers Squibb Company (US) | 2004-08-18 | — | — | EP | claimed |
| US-20030186983-A1 | C-5 Modified indazolylpyrrolotriazines | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-02 | — | — | US | claimed |
| WO-2003042172-A2 | C-5 MODIFIED INDAZOLYLPYRROLOTRIAZINES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-05-22 | — | — | WO | claimed |
| EP-1446401-B1 | C5-modified indazolylpyrrolotriazines | BRISTOL MYERS SQUIBB CO (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20050209235-A1 | C-5 Modified indazolylpyrrolotriazines | MASTALERZ HAROLD | 2005-09-22 | — | — | US | disclosed |
| US-6908916-B2 | C-5 modified indazolylpyrrolotriazines | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186983-A1 | C-5 Modified indazolylpyrrolotriazines | ERBB2, ERBB4, EGFR | EGFR 3/4885ERBB2 1/4885MET 50/4885 |
| US-20050209235-A1 | C-5 Modified indazolylpyrrolotriazines | ERBB2, ERBB4, EGFR | EGFR 3/4885ERBB2 1/4885MET 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.